Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation

Publisher： Bentham Science Publishers

E-ISSN： 1875-614x|12|1|94-99

ISSN： 1871-5230

Source： Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol.12, Iss.1, 2013-03, pp. : 94-99

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects

By Khosravan Reza   Grabowski Brian A.   Wu Jing-Tao   Joseph-Ridge Nancy   Vernillet Laurent  

Clinical Pharmacokinetics, Vol. 45, Iss. 8, 2006-01 ,pp. : 821-841

Adis International

Access to resources Recommend Favorite

Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

By Schumacher Jr   H Ralph  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 7, 2005-07 ,pp. : 893-903

Informa Healthcare

Access to resources Recommend Favorite

Augmenting the Xanthine Oxidase Inhibitory Activity of Febuxostat by its Structural Modification

By  

Letters in Drug Design & Discovery, Vol. 11, Iss. 2, 2014-02 ,pp. : 207-210

Bentham Science Publishers

Access to resources Recommend Favorite

2-Arylquinazolin-4(3H)-ones: Inhibitory Activities Against Xanthine Oxidase

By  

Medicinal Chemistry, Vol. 12, Iss. 1, 2016-02 ,pp. : 54-62

Bentham Science Publishers

Access to resources Recommend Favorite

Xanthine oxidase inhibitors: a patent survey

By Kumar Raj     Sharma Sahil   Singh Rajveer  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 7, 2011-07 ,pp. : 1071-1108

Informa Healthcare

Access to resources Recommend Favorite